^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug Class:CAR-T immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    TCT-ASTCT-CIBMTR 2022
    Title:

    Paediatric Experience of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

    Published date:
    02/11/2022
    Excerpt:
    CR rate at 28 days post-infusion was 100%....CART therapy is a safe and effective therapy with excellent CR rates at 28 days post-infusion for children with Ph+ ALL.